You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,943,575


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,943,575
Title:Pharmaceutical compositions of tenecteplase
Abstract: Pharmaceutical compositions of tenecteplase that are safe and effective in the treatment of acute ischemic stroke compared with the known compositions are disclosed. The compositions of the invention are invented based on a series of testing trials on the different amounts of the TNK and isolating specific amount that is optimally suitable in terms of desired effects of TNK in the treatment of acute ischemic stroke.
Inventor(s): Mishra; Maheshwari Kumar (Pune, IN), Bhandari; Pritiranjan (Pune, IN), Singh; Sanjay (Pune, IN)
Assignee: Gennova Biopharmaceuticals Limited (Pune, IN)
Application Number:15/136,614
Patent Claims:1. A method for treating acute ischemic stroke in a human subject in need thereof, the method comprising administering to the human 0.20 mg/kg body weight of tenecteplase as a single intravenous bolus injection, wherein the tenecteplase is produced by a process comprising expression in a mammalian cell line by a perfusion-based continuous fermentation process that provides at least 80% single-chain tenecteplase protein after purification.

2. The method of claim 1, wherein the bolus injection is given over not more than 10 seconds.

3. The method of claim 2, wherein the human is administered the tenecteplase within 6 hours of the onset of the acute ischemic stroke incident.

4. The method of claim 1, wherein the human is administered the tenecteplase within 6 hours of the onset of the acute ischemic stroke incident.

5. A method for treating acute ischemic stroke in a human subject in need thereof, the method comprising administering to the human 0.20 mg/kg body weight of tenecteplase as a pharmaceutical composition in a single intravenous bolus injection, wherein the pharmaceutical composition comprises (a) tenecteplase, (b) a pharmaceutically acceptable inorganic buffer, (c) a pharmaceutically acceptable stabilizing agent, and (d) optionally, a pharmaceutically acceptable carrier, where the tenecteplase is produced by a process comprising expression in a mammalian cell line by a perfusion-based continuous fermentation process that provides at least 80% single-chain tenecteplase protein after purification.

6. The method of claim 5, wherein the bolus injection is given over not more than 10 seconds.

7. The method of claim 6, wherein the human is administered the tenecteplase within 6 hours of the onset of the acute ischemic stroke incident.

8. The method of claim 5, wherein the human is administered the tenecteplase within 6 hours of the onset of the acute ischemic stroke incident.

9. The method of claim 5, wherein the buffer is phosphoric acid.

10. The method of claim 5, wherein the stabilizing agent is L-arginine.

11. The method of claim 5, wherein the stabilizing agent is a polysorbate.

12. A method for treating acute ischemic stroke in a human subject in need thereof, the method comprising administering to the human 0.20 mg/kg body weight of tenecteplase as a pharmaceutical composition in a single intravenous bolus injection, wherein the pharmaceutical composition comprises tenecteplase, phosphoric acid, L-arginine, and polysorbate, where the tenecteplase is produced by a process comprising expression in a mammalian cell line by a perfusion-based continuous fermentation process that provides at least 80% single-chain tenecteplase protein after purification.

13. The method of claim 12, wherein the bolus injection is given over not more than 10 seconds.

14. The method of claim 13, wherein the human is administered the tenecteplase within 6 hours of the onset of the acute ischemic stroke incident.

15. The method of claim 12, wherein the human is administered the tenecteplase within 6 hours of the onset of the acute ischemic stroke incident.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.